IKM

IKM is a clinical-stage biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. The company's primary focus is on the development of next-generation biologics, particularly monoclonal antibodies targeting key cytokines in the inflammatory cascade such as IL-17 and IL-23. Their lead programs are currently in mid-stage clinical trials, aiming to provide more effective and safer treatment options for patients with chronic conditions like psoriasis and psoriatic arthritis. IKM leverages advanced protein engineering to optimize the therapeutic profile of its candidates, seeking to improve upon existing standard-of-care treatments.